James H. Doroshow, M.D.

Dr. James H. Doroshow has served as the Director of the Division of Cancer Treatment and Diagnosis since 2004. He is also a Senior Investigator of his own lab in the Developmental Therapeutics Branch of the NCI’s intramural Center for Cancer Research.

From 1983 to 2004, he was the Chairman of the City of Hope Comprehensive Cancer Center’s Department of Medical Oncology and Therapeutics Research, and Associate Cancer Center Director for Clinical Investigation.

Dr. Doroshow has authored over 500 full-length publications in the areas of cancer molecular pharmacology, the role of oxidant stress in tumor cell signal transduction, and novel therapeutic approaches to treating solid tumors.

Selected Publications

• Prindiville SA, Mandrekar SJ, Meropol NJ, Denicoff A, Grad O, Hautala JA, Doroshow JH: Streamlining the Conduct of Cancer Clinical Trials: New Standard Data Collection Practices for National Cancer Institute Late Phase Clinical Studies. J Natl Cancer Inst. 2024 Sep 26.
• Harris LN, Blanke CD, Erba HP, et al.: The New NCI Precision Medicine Trials. Clin Cancer Res. 2023 Dec 1;29(23):4728-4732.
• Chen AP, Sharon E, Doroshow JH, et al.: Atezolizumab for Advanced Alveolar Soft Part Sarcoma. N Engl J Med. Sep 7;389(10):911-921. 2023. 
• Wang SL, Wu Y, Konaté M, Lu J, Mallick D, Antony S, Meitzler JL, Jiang G, Dahan I, Juhasz A, Diebold B, Roy K, Doroshow JH: Exogenous DNA enhances DUOX2 expression and function in human pancreatic cancer cells by activating the cGAS-STING signaling pathway. Free Radic Biol Med. 2023 Aug 20:205:262-274.
• Rodriguez H, Zenklusen JC, Staudt LM, Doroshow JH, Lowy, DR: The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. Apr 1;184(7):1661-1670. 2021.

Additional Links to Scientific Publications

• SCOPUS

Education

• M.D., Harvard Medical School, Boston, MA
• A.B., Harvard College, Cambridge, MA